New Optimum® Class VI Dispensing Components Provide Assurance to Medical Manufactures
15.9.2020 17:02:00 EEST | Business Wire | Press release
Nordson EFD , a Nordson company (NASDAQ: NDSN), the world’s leading precision fluid dispensing systems manufacturer, introduces Optimum® Class VI fluid dispensing components made from 100% virgin resin that is Class VI certified by the U.S. Pharmacopeial Convention (USP).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005026/en/
Optimum Class VI dispensing components are manufactured from USP Class VI resin, making these biocompatible components ideal for medical device manufacturing. (Photo: Business Wire)
“We wanted to make it easier for medical manufacturers to provide the traceability required to meet strict regulatory standards,” said Felicitas Stuebing, global product line specialist at Nordson EFD. “Meeting the most stringent USP Class designation is not only a testament to the quality of our components, it provides peace of mind that our components are safe to use in medical manufacturing processes.”
New Optimum Class VI dispensing components include 3cc, 5cc, 10cc, 30cc, and 55cc syringe barrels and pistons, in addition to end caps and tip caps. These biocompatible components do not have a colorant, making them easier for engineers to document for regulatory approvals.
In addition, these first-to-market medical-grade dispensing components feature the same highly-engineered design as standard Optimum components. The Class VI syringe barrels feature ZeroDraft™ walls with consistent internal diameters that maintain an airtight seal with Class VI pistons to provide accurate, repeatable fluid deposits used in bonding, coating, and other medical assembly processes.
These components also pass the same rigorous quality standards Nordson EFD maintains to ensure a consistent product that provides consistent performance.
Ethylene oxide (ETO), autoclave, and gamma sterilization methods were tested to determine the impact on Optimum Class VI dispensing components. Those results can be found in the product data sheet, though Nordson EFD states that all customers must to do their own testing to validate their processes.
For more information, visit Nordson EFD on the web at nordsonefd.com/ClassVI, linkedin.com/company/nordson-efd, email at info@nordsonefd.com, or call +1 401.431.7000 or 800.556.3484.
About Nordson EFD
Nordson EFD designs and manufactures precision fluid dispensing systems for benchtop assembly processes and automated assembly lines. By enabling manufacturers to apply the same amount of adhesive, lubricant or other assembly fluid to every part, every time, EFD dispensing systems are helping companies in a wide variety of industries increase throughput, improve quality, and lower their production costs. Other fluid management capabilities include high-quality syringe barrels and cartridges for packaging one- and two-component materials, along with a wide variety of fittings, couplers and connectors for controlling fluid flow in medical, biopharmaceutical and industrial environments. The company is also a leading formulator of specialty solder pastes for dispensing and printing applications in the electronics industry.
About Nordson Corporation
Nordson engineers, manufactures, and markets differentiated products and systems used for dispensing and processing adhesives, coatings, polymers, sealants and biomaterials; and for managing fluids, testing and inspecting for quality, treating surfaces and curing. These products are supported with extensive application expertise and direct global sales and service. We serve a wide variety of consumer non-durable, consumer durable and technology end markets including packaging, nonwovens, electronics, medical, appliances, energy, transportation, building and construction, and general product assembly and finishing. Founded in 1954 and headquartered in Westlake, Ohio, the company has operations and support offices in more than 30 countries. Visit Nordson on the web at nordson.com, twitter.com/Nordson_Corp or facebook.com/nordson.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005026/en/
Contact information
Nordson EFD
Global
Natalie Tomasso
Marketing Communications Specialist
+1-401-431-7173 (USA); natalie.tomasso@nordsonefd.com
Europe
+44 (0) 1582 666334; infoefd.europe@nordsonefd.com
China
+86 (21) 3866 9006; china@nordsonefd.com
Japan
+81 (03) 5762 2760; japan@nordsonefd.com
Korea
+82 (31) 7368321; korea@nordsonefd.com
SEAsia
+65 6796 9522; sin-mal@nordsonefd.com
India
+91 80 4021 3600; india@nordsonefd.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group Unveils Ling-3.0-Flash Delivering Top-Tier Performance at a Fraction of the Parameter Scale27.7.2026 09:00:00 EEST | Press release
Ant Group today announced the release of Ling-3.0-Flash, a next-generation native hybrid-reasoning foundational model engineered specifically for production-grade AI agent workflows. Designed to deliver rapid response capabilities, it serves as a high-speed execution node that offers a superior balance of intelligence density and cost-efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260726584441/en/ Ling-3.0-Flash delivers strong performance across multiple core benchmarks. Featuring 124B total parameters with only 5.1B active parameters per token, Ling-3.0-Flash achieves remarkable performance despite its streamlined footprint. It matches or surpasses industry-leading models with two to three times its parameter scale across core benchmarks, including foundational reasoning, instruction following, and long-context processing. Architectural Innovation for Efficiency Ling-3.0-Flash moves away from the traditional ap
SES Statement On FCC Upper C-band Auction Decision27.7.2026 08:30:00 EEST | Press release
SES, a leading space solutions company, issued the following statement following the U.S. Federal Communications Commission approval of the Upper C-band Report & Order that makes 160 megahertz of the Upper C-band available in the contiguous United States for flexible-use, next-generation terrestrial wireless services via a system of competitive bidding. The required auction of the Upper C-band will be completed no later than July 2027, with spectrum clearing deadlines in 2030 and 2031. Gross incentive payments of approximately $5.6 billion to SES are contingent on spectrum clearing within the transition deadlines. The Order also confirms reimbursement of reasonable and necessary Upper C-band transition costs as approved by the clearinghouse. SES CEO Adel Al-Saleh Commented: “We commend Chairman Carr and the FCC staff for their diligence, speed, and hard work. We remain fully committed to working cooperatively with the FCC and all stakeholders as the process progresses. We are pleased t
LTM and Cognition Partner to Reduce Cyber Risk in Financial Services with Devin27.7.2026 08:00:00 EEST | Press release
LTM, the Business Creativity partner to the world's largest enterprises, today announced a strategic partnership with Cognition, the AI lab behind the software engineering agent Devin. As a part of this partnership, LTM has onboarded Devin, Cognition’s Autonomous AI Engineer as part of BlueVerseTM RightLogic. LTM BlueVerse RightLogic, is a cybersecurity assessment and risk assurance framework designed to help enterprises identify, assess and remediate cyber exposure as they accelerate AI adoption. Together, the companies will prioritize financial services sector, where Devin is most proven and where LTM brings deep institutional expertise. As AI adoption accelerates, many financial institutions are facing a widening gap between innovation and cyber risk visibility. BlueVerse RightLogic closes this gap by autonomously identifying, prioritizing and remediating vulnerabilities across banking infrastructure, applications, AI systems, software supply chains and governance—including exploits
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 14:00:00 EEST | Press release
Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performance, reliability and trusted supply chains. Its drones support national security and public-safety operations, sear
Enhertu ® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 14:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from theDESTINY-Breast09 phase 3 trialpresented at the 2025 American Society of Clinical Oncology Annual Meeting and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DESTI
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom